Literature DB >> 10452291

The role of arterial embolization in renal cell carcinoma.

D Kalman1, E Varenhorst.   

Abstract

Twenty-five years ago arterial embolization was introduced to facilitate the surgical excision of the carcinomatous kidney or to palliate symptoms, such as haemorrhage from non-resectable tumours. The role of this technique in the therapeutic armamentarium has been a source of debate in the literature. We reviewed all the available literature. A total of 389 papers were evaluated. Fifty-one publications and 3225 case histories met explicit entry criteria for inclusion. Until now no prospective randomized study of this approach to the management of renal carcinoma has been published. In the majority of studies the patients are grouped together irrespective of indication, i.e. pre-operative or palliative. Few articles are prospective or contain clear information regarding tumour stage, indication and adequate follow-up. Although we are not able to distinguish with certainty the effect of embolization on the course of the disease, it seems that complete pre-operative renal artery embolization facilitates the excision of large vein-invading tumours. The optimal delay between embolization and operation is probably one day. The embolization material of choice is ethanol. Palliative embolization in non-operable tumours with serious haemorrhage seems to have been successful in most cases. The scientific basis for the implementation of renal artery embolization in renal cell carcinoma is weak. We believe that either controlled trials or parallel prospective cohort studies should be undertaken to compare treatment of selected locally advanced renal carcinomas with and without embolization.

Entities:  

Mesh:

Year:  1999        PMID: 10452291     DOI: 10.1080/003655999750015934

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  23 in total

1.  Percutaneous radio frequency ablation for hematuria.

Authors:  B J Wood; J Grippo; C P Pavlovich
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

2.  Renal artery embolisation prior to radical nephrectomy for renal cell carcinoma: when, how and why?

Authors:  R Loffroy; P Rao; S Ota; J F Geschwind
Journal:  Br J Radiol       Date:  2010-07       Impact factor: 3.039

3.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

4.  Re: Pilot study of transcatheter arterial ethanol emolization under closed renal circuit for large renal cell carcinomas.

Authors:  G McNeill; D Halpenny; A Snow; W C Torreggiani
Journal:  Eur Radiol       Date:  2008-10-30       Impact factor: 5.315

5.  High-speed, clinical-scale microfluidic generation of stable phase-change droplets for gas embolotherapy.

Authors:  David Bardin; Thomas D Martz; Paul S Sheeran; Roger Shih; Paul A Dayton; Abraham P Lee
Journal:  Lab Chip       Date:  2011-10-20       Impact factor: 6.799

6.  Preoperative embolization.

Authors:  William S Rilling; Gene W Chen
Journal:  Semin Intervent Radiol       Date:  2004-03       Impact factor: 1.513

Review 7.  The evolution of cancer surgery and future perspectives.

Authors:  Lynda Wyld; Riccardo A Audisio; Graeme J Poston
Journal:  Nat Rev Clin Oncol       Date:  2014-11-11       Impact factor: 66.675

Review 8.  Role of embolization in the treatment of renal masses.

Authors:  David Li; Bradley B Pua; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

Review 9.  Renal Embolization: Current Recommendations and Rationale for Clinical Practice.

Authors:  Raja S Ramaswamy; Olaguoke Akinwande; Tatulya Tiwari
Journal:  Curr Urol Rep       Date:  2018-02-05       Impact factor: 3.092

10.  Renal artery embolization using a new liquid embolic material obtained by partial hydrolysis of polyvinyl acetate (Embol): initial experience in six patients.

Authors:  S I Park; D Y Lee; J Y Won; S Park
Journal:  Korean J Radiol       Date:  2000 Jul-Sep       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.